The current course of acute respiratory infections and the possibility of pathogenetic therapy.
https://doi.org/10.21518/2079-701X-2018-20-14-16
Abstract
Acute respiratory viral infections (ARVI) are leading in the structure of the general morbidity of the population. To date, more than 200 viruses that affect the respiratory tract and ENT organs are known [1]. The reservoir of ARVI pathogens is only human, the highest incidence is observed in the cold season [8]. It is also possible to infect several ARVI pathogens together, which is accompanied by a severe course of the disease and the addition of bacterial complications [6, 7]. To date, prevention and treatment of ARVI, both in adults and children, is one of the important tasks facing the medical community [1, 2]. The etiotropic therapy of most ARVI has not been developed, and the use of interferon preparations and interferon synthesis inducers has not proved their clinical efficacy [11]. As an alternative, bioregulatory agents that have proven their safety and clinical efficacy can be used [12]. The article presents numerous studies of clinical efficacy and safety of the bioregulatory drug Engystol in different age groups.
About the Authors
S. B. Krutikhina
I.M. Sechenov First Moscow State Medical University (Sechenov University), University children’s clinical hospital
Russian Federation
Russian Federation
E. A. Yablokova
I.M. Sechenov First Moscow State Medical University (Sechenov University), University children’s clinical hospital
Russian Federation
Russian Federation
References
1. Kaluzhin OV. Acute respiratory viral infections: current challenges, antiviral response, immunoprophylaxis and immunotherapy. M.: MIA, 2013.
2. Debiaggi M., Canducci F., Ceresola E.R., Clementi M. The role of infections and coinfections with newly identified and emerging respiratory viruses in children. Virology Journal, 2012, 9.
3. Krutikhina SB, Yablokova EA. Acute respiratory viral infections in children: modern possibilities for homeopathic remedies. RMJ, 2016, 18 (24): 1191-1195.
4. Kanner EV, Krutikhina SB, Gorelov AV. Results of 15-year study of metapneumovirus infection. Literature review. Meditsinsky Sovet, 2017, 9: 48-50.
5. Kanner EV, Krutikhina SB, Gorelov AV. Bocavirus infection in children at the current stage. Literature review. Meditsinsky Sovet, 2017, 5: 34-37.
6. Mazunik NN. Clinical features, diagnosis and treatment of mixed forms of acute respiratory viral infections in children: extended abstract of Cand. Sci. (Med.) Dissertation. M., 2007.
7. Kanner EV, Gorelov AV. Combined acute respiratory infections in children. Epidemiologiya i Infekcionnye Bolezni. Aktualnye Voprosy, 2017, 3: 72-77.
8. Kozlowski D. Physical interventions to interrupt or reduce the spread of respiratory viruses. International Journal of Evidence-Based Healthcare, 2012, 10(2): 159-161.
9. Kozlovsky AA, Pyrkova IV. Experience in using Groprinosin to treat acute respiratory viral infections in children. Mezhdunarodnye Obzory: Klinicheskaya Praktika i Zdorovie, 2014, 4: 77-83, 2014, 4: 77-83.
10. Bulgakova VA. Acute respiratory infections in children: rational choice of pharmacotherapy. Spravochnik Pediatra, 2011, 8: 28-37.
11. Romantsov MG, Ershov FI, Kovalenko AL. Antiviral drugs for the treatment of ARVI and influenza in children (clinical review). Fundamentalnye Issledovaniya, 2010, 9: 76–87.
12. Selkova EP, Semenenko TA, Leneva IA. Naturopathic remedies for the treatment and prevention of influenza and ARVI. Lechaschy Vrach, 2007, 2: 76-79
13. Roeska K., Seilheimer B. Antiviral activity of Engystol® and Gripp-Heel®: an in-vitro assessment. J Imm Based Ther Vacc, 2010, 8: 6.
14. Fimiani V., Cavallaro A., Ainis O., Bottari C. Immunomodulatory effect of the homoeopathic drug Engystol-N on some activities of isolated human leukocytes and in whole blood. Immunopharmacol Immunotoxicol, 2000, 22(1): 103-115.
15. Ricken K.H. The Treatment of Infection Predisposition with Biotherapeutic Medication. Biol Ther, 1993, XI(1): 50-54.
16. Drugs.com, Aconite, at: http://www.drugs.com/ npp/aconite.html. Accessed October 2011.
17. Stafford G.I., Pedersen M.E., van Staden J., Jager A.K. Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J Ethnopharmacol, 2008, 119(3): 513-537.
18. Heilmann A. A combination injection preparation as a prophylactic for flu and common colds. Biol Ther, 1994, VII(4): 249-253.
19. Schmiedel V., Klein P. A complex homeopathic preparation for the symptomatic treatment of upper respiratory infections associated with the common cold: an observational study. Explore, 2006, 2: 109-114.
20. Matusiewicz R. The effect of a homeopathic preparation on the clinical condition of patients with corticosteroiddependent bronchial asthma. Biomed Ther, 1997, XV(3): 70-74.
21. Torbicka E., Brzozowska-Binda A., Wilczynski J., Uzerowicz A. RSV Infections in Infants: Therapy with a Homeopathic Preparation. Biomed Ther, 1998, XVI(4): 256-260.
22. Memish Z.A., Alhakeem R., Stephens G.M. Saudi Arabia and the emergence of a novel coronavirus. East Mediterr Health J, 2013, 19(1): 7–11.
Review
For citations:
Krutikhina SB, Yablokova EA. The current course of acute respiratory infections and the possibility of pathogenetic therapy. Meditsinskiy sovet = Medical Council. 2018;(20):14-16. (In Russ.) https://doi.org/10.21518/2079-701X-2018-20-14-16
Views:
877
Email this article 